#1 Clinical Trials Search in Europe

Mk-1167

MK-1167 is an investigational drug currently being studied in clinical trials for the treatment of Alzheimer’s disease dementia. These trials aim to evaluate the safety, efficacy, and pharmacokinetics of MK-1167 when used alone or in combination with existing Alzheimer’s treatments. The studies involve both healthy participants and those diagnosed with Alzheimer’s disease, exploring various dosing regimens and potential drug interactions.

Table of Contents

What is MK-1167?

MK-1167 is a new experimental drug being developed to treat Alzheimer’s disease dementia, which is the most common type of dementia[1]. Alzheimer’s disease is a progressive brain disorder that affects memory, thinking skills, and the ability to carry out simple tasks. MK-1167 is designed to be used alongside existing treatments to potentially improve symptoms and quality of life for patients with mild to moderate Alzheimer’s disease.

How MK-1167 Works

While the exact mechanism of action for MK-1167 is not fully described in the available information, it is being studied as an adjunctive therapy. This means it is intended to be used in combination with standard Alzheimer’s treatments, specifically acetylcholinesterase inhibitors (AChEIs)[1]. AChEIs are a class of drugs that work by increasing levels of a brain chemical called acetylcholine, which is important for memory and thinking.

By combining MK-1167 with AChEIs, researchers hope to enhance the overall effectiveness of Alzheimer’s treatment and provide better symptom management for patients.

Clinical Trials

MK-1167 is currently being studied in several clinical trials to evaluate its safety, effectiveness, and how it interacts with other medications. Here are some key points about these trials:

  • A Phase 2 study (MK-1167-008) is testing different doses of MK-1167 (0.3 mg, 1 mg, and 3 mg) against a placebo in patients with mild to moderate Alzheimer’s disease dementia[1].
  • Another study (MK-1167-007) is specifically looking at how MK-1167 works in patients who are already taking a stable dose of donepezil, a common Alzheimer’s medication[2].
  • Researchers are also conducting studies to understand how MK-1167 interacts with other drugs, such as diltiazem, a medication used for heart conditions[3].
  • A study in healthy elderly participants (MK-1167-004) is being conducted to assess the safety and tolerability of MK-1167 in older adults without Alzheimer’s disease[4].

Potential Benefits

The main goals of MK-1167 treatment are to:

  • Improve memory and thinking skills in people with Alzheimer’s disease[1].
  • Enhance the effectiveness of existing Alzheimer’s treatments when used in combination[2].
  • Potentially slow down the progression of cognitive decline in Alzheimer’s patients.

Researchers are using various tests to measure these potential benefits, including:

  • The Alzheimer’s Disease Assessment Scale-11-item Cognitive Subscale (ADAS-Cog11): This test evaluates memory, orientation, attention, language, and other cognitive functions[1].
  • The Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC): This assessment looks at overall changes in a patient’s condition from the start of treatment[1].
  • The Alzheimer’s Disease Cooperative Study Activities of Daily Living (ADCS-ADL): This scale measures how well patients can perform everyday tasks[1].

Safety and Side Effects

As with any new medication, safety is a primary concern in the development of MK-1167. The clinical trials are closely monitoring for any adverse events (AEs), which are unexpected medical issues that may occur during treatment[1][2][3][4]. These may or may not be related to the study drug.

The trials are tracking:

  • The number of participants who experience one or more adverse events.
  • The number of participants who have to stop taking the study drug due to adverse events.
  • Any changes in vital signs, laboratory tests, or other health indicators.

It’s important to note that as MK-1167 is still in the testing phase, a complete list of potential side effects is not yet available. This information will be gathered and analyzed as the clinical trials progress.

Dosage and Administration

MK-1167 is being studied in various dosage forms and schedules:

  • It is taken orally, usually in the form of capsules[1][2].
  • Different dosing regimens are being tested, including:
    • Once daily (QD) dosing at 0.3 mg, 1 mg, or 3 mg for up to 24 weeks[1].
    • A loading dose (higher initial dose) followed by a maintenance dose. For example, 6 mg for 7 days, then 3 mg daily for the remaining treatment period[2].
  • The optimal dosage and schedule will be determined based on the results of these clinical trials.

Future Prospects

MK-1167 is still in the early stages of development, and more research is needed to fully understand its potential benefits and risks. If the current clinical trials show promising results, larger studies may be conducted to further evaluate its effectiveness and safety.

It’s important for patients and caregivers to remember that while MK-1167 shows promise, it is not yet approved for general use. Anyone interested in new treatments for Alzheimer’s disease should discuss current options with their healthcare provider and consider participating in clinical trials if appropriate.

Aspect Details
Drug Name MK-1167
Condition Studied Alzheimer’s Disease Dementia
Trial Phases Phase 1 and Phase 2
Administration Oral capsules
Dosing Various regimens, including 0.3 mg, 1 mg, 3 mg, and 6 mg
Duration Ranging from a few weeks to approximately 24 weeks
Primary Outcomes Safety, tolerability, changes in cognitive function (ADAS-Cog11)
Secondary Outcomes Global function (ADCS-CGIC), daily activities (ADCS-ADL), pharmacokinetics
Combination Therapy Studied with acetylcholinesterase inhibitors (e.g., donepezil)
Special Populations Healthy elderly adults, Alzheimer’s disease patients

FAQ

  • What is MK-1167? MK-1167 is an experimental drug being tested for the treatment of Alzheimer's disease dementia. It is being studied as a potential therapy to improve memory and cognitive function in people with mild to moderate Alzheimer's disease.
  • How is MK-1167 being studied in clinical trials? MK-1167 is being studied in various clinical trials, including phase 1 and phase 2 studies. These trials are evaluating its safety, how well people tolerate it, and its effectiveness in improving Alzheimer's symptoms when used alone or in combination with other Alzheimer's medications.
  • What are the main goals of the MK-1167 clinical trials? The main goals of the MK-1167 clinical trials are to determine if it can improve memory and thinking in people with Alzheimer's disease, assess its safety profile, understand how the body processes the drug, and evaluate its potential interactions with other medications.
  • Who can participate in MK-1167 clinical trials? Different MK-1167 trials have various eligibility criteria. Some studies involve healthy elderly adults, while others focus on people diagnosed with mild to moderate Alzheimer's disease dementia. Some trials also include participants who are already taking standard Alzheimer's treatments like acetylcholinesterase inhibitors.
  • How long do the MK-1167 clinical trials typically last? The duration of MK-1167 clinical trials varies depending on the study design. Some trials last for a few weeks, while others can extend up to 24 weeks or longer. The length of the trial depends on factors such as the study phase, dosing regimen, and specific research objectives.

Ongoing Clinical Trials on Mk-1167

  • A study testing MK-1167 added to current treatment in patients with mild to moderate Alzheimer’s disease dementia

    Not recruiting

    1
    Investigated drugs:
    Italy The Netherlands Spain

Glossary

  • Alzheimer's Disease Dementia (AD dementia): The most common type of dementia, characterized by progressive memory loss, cognitive decline, and changes in behavior and daily functioning.
  • Acetylcholinesterase inhibitor (AChEI): A type of medication commonly used to treat Alzheimer's disease that works by increasing levels of a brain chemical called acetylcholine, which is important for memory and thinking.
  • Placebo: An inactive substance that looks like the drug being tested but contains no active medication. It is used as a comparison to evaluate the effectiveness of the actual drug.
  • ADAS-Cog11: Alzheimer's Disease Assessment Scale-11-item Cognitive Subscale, a test used to measure cognitive function in people with Alzheimer's disease.
  • ADCS-CGIC: Alzheimer's Disease Cooperative Study Clinical Global Impression of Change, a measure used by clinicians to assess overall changes in a patient's condition during a clinical trial.
  • ADCS-ADL: Alzheimer's Disease Cooperative Study Activities of Daily Living, a scale used to assess a person's ability to perform everyday tasks.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and eliminated.
  • AUC (Area Under the Curve): A measure used in pharmacokinetics to represent the total exposure to a drug over time.
  • Cmax: The maximum concentration of a drug in the blood after it has been administered.
  • Half-life: The time it takes for the concentration of a drug in the body to decrease by half.

References

  1. https://clinicaltrials.gov/study/NCT06721156
  2. https://clinicaltrials.gov/study/NCT06285240
  3. https://clinicaltrials.gov/study/NCT06703463
  4. https://clinicaltrials.gov/study/NCT06625840